t
Haleon plc announced on 1 September 2025 that as at 31 August 2025, its total number of issued ordinary shares of £0.01 each was 8,959,221,411. Of these, 3,880,205 shares were held in treasury. Consequently, the total number of ordinary shares with voting rights was 8,955,341,206.
| Date | 1 Sept 2025 |
| Time | 10:30:00 |
| Category | Capital structure |
| ID | 4482X |
Haleon plc: Total Voting Rights and Capital
1 September 2025: As at 31 August 2025 the total number of shares issued by Haleon plc ("Haleon" or the "Company") is 8,959,221,411 ordinary shares of £0.01 each, of which 3,880,205 are held as treasury shares.
Therefore, the number of ordinary shares with voting rights is 8,955,341,206 and this figure should be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.
Notifiable interests in Haleon may be sent to: [email protected]
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.
For more information, please visit www.haleon.com.